Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT ...
Medical Health News,
CUMBERLAND, Rhode Island, and LA JOLLA, California, Jan. 16, 2019 /PRNewswire/ -- The results of the NT-501 Phase 2 study…
Neurotech Pharmaceuticals, Inc., y el Lowy Medical Research Institute publican un estudio de fase II con el NT-501
PR Newswire,
-., y el Lowy Medical Research Institute anuncian la publicación de los resultados de un estudio de fase II con el NT-501…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Padova News,
– MacTel type 2 is a rare macular degenerative disease typically diagnosed in middle age.
COMUNICADO: Neurotech Pharmaceuticals, Inc., y el Lowy Medical Research Institute publican un estudio de fase II con el NT-501 (2)
Europa Press,
El Lowy Medical Research Institute (LMRI) es una institución privada y carente de ánimo de lucro que se dedica a la investigación…
News story from Finanz Nachrichten on Wednesday 16 January 2019
Finanz Nachrichten,
Jan 16, 2019, 6:34 am PST Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Business Journals,
CUMBERLAND, R.I. and LA JOLLA, Calif., Jan. 16, 2019 /PRNewswire/ -- The results of the NT-501 Phase 2 study sponsored by…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Biospace,
CUMBERLAND, R.I. and LA JOLLA, Calif., Jan. 16, 2019 /PRNewswire/ -- The results of the NT-501 Phase 2 study sponsored by…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
WFMJ,
SOURCE Neurotech Pharmaceuticals, Inc. CUMBERLAND, R.I. MacTel type 2 is a rare macular degenerative disease typically…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Kuam,
SOURCE Neurotech Pharmaceuticals, Inc. CUMBERLAND, R.I. MacTel type 2 is a rare macular degenerative disease typically…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
WBOC 16,
SOURCE Neurotech Pharmaceuticals, Inc. CUMBERLAND, R.I. MacTel type 2 is a rare macular degenerative disease typically…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
CBS8,
SOURCE Neurotech Pharmaceuticals, Inc. CUMBERLAND, R.I. MacTel type 2 is a rare macular degenerative disease typically…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
ABC 6 News WLNE,
1 The Macular Telangiectasia Type 2-Phase 2 CNTF Research Group, Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
KLKN-TV Eyewitness News,
1 The Macular Telangiectasia Type 2-Phase 2 CNTF Research Group, Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Erie News Now,
1 The Macular Telangiectasia Type 2-Phase 2 CNTF Research Group, Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
News Channel,
SOURCE Neurotech Pharmaceuticals, Inc. CUMBERLAND, R.I. MacTel type 2 is a rare macular degenerative disease typically…
Neurotech Pharmaceuticals, Inc. und Lowy Medical Research Institute veröffentlichen Ergebnisse der Phase 2 der NT-501-Studie
PR Newswire,
CUMBERLAND, Rhode Island und LA JOLLA, Kalifornien, 16. Januar 2019 /PRNewswire/ -- Die Ergebnisse der von Neurotech…
Neurotech Pharmaceuticals, Inc. et le Lowy Medical Research Institute annoncent la publication des résultats de l'étude de phase 2 sur le NT-501
PR Newswire,
CUMBERLAND, Rhode Island, et LA JOLLA, Californie, 16 janvier 2019 /PRNewswire/ -- Les résultats de l'étude de phase 2 sur le NT…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
PR Newswire,
CUMBERLAND, R.I. and LA JOLLA, Calif., Jan. 16, 2019 /PRNewswire/ -- The results of the NT-501 Phase 2 study sponsored by…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Ticker Tech,
CUMBERLAND, R.I. and LA JOLLA, Calif., Jan. 16, 2019 /PRNewswire/ -- The results of the NT-501 Phase 2 study sponsored by…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Benzinga,
CUMBERLAND, R.I. and LA JOLLA, Calif., Jan. 16, 2019 /PRNewswire/ -- The results of the NT-501 Phase 2 study sponsored by…
Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results
Affaritaliani.it,
- MacTel type 2 is a rare macular degenerative disease typically diagnosed in middle age.